Growth Hormone Releasing Peptide 2
Peptide Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Molecular Formula: C45H55N9O6 Molar Mass: 817.9 g/mol CAS Number: 158861-67-7
Important Notification: All of our products and services listed in this website are for research or production use only, not for direct human use.
The polypeptide GHRP 2 is a secretogogue that has a molecular formula of C45H55N9O6 and a molecular weight of 817.9. It is comprised of six different amino acids, thus making it a hexipeptide. Its name is an acronym for Growth Hormone Releasing Peptide. It can be sometimes known as GHRP or KP-102.
GHRP – 2 at a Glance
Scientific study that has been based on animal test subjects has determined that GHRP-2’s overall functionality and operational mechanic can be primarily tied to the production of the pituitary gland; the pea-sized gland that is located at the bottom of the hypothalamus at the base of the brain which is chiefly responsible for regulating several of the body’s basic regulatory functions, ranging from growth and metabolism to internal water regulation and pain relief. GHRP 2 has been shown to elevate the functionality of the pituitary gland by promoting the stimulation of secretions from somatropic cells from within the gland.
At the same time, it has been shown to prevent somatostatin; the peptide secretion that regulates the endocrine system and affects neurotransmission and cellular proliferation via interaction with G-coupled receptors. In addition, scientific study based on animal test subjects has determined that the peptide can boost levels of calcium ion influx, which in turn can also stimulate the production of more secretions related to growth.
GHRP – 2 and Ghrelin
Another key component of GHRP 2’s overall operational mechanics can be traced to the peptide’s relationship with the stomach – specifically, its relationship with a self-regulated 28 amino acid enzyme known as ghrelin.
In essence, the secretion of ghrelin serves two purposes:
- It causes the sensation of hunger within animal test subjects
- It balances the secretion of leptin, an enzyme whose expression creates the sensation of feeling full
GHRP-2 has been shown to boost the levels of ghrelin production, thus causing an animal test subject to feel a sense of hunger for a longer, more substantial period of time. This then will elevate the desire that an animal test subject will have in regards to consuming food. In turn, this elevated food intake converts to the boost in fuel that is ultimately a key player in GHRP-2’s ability to boost protein synthesis.
GHRP – 2 and IGF-1
Additional scientific study that has been based on animal test subject has shown that GHRP 2’s functionality enables it to work in conjunction with the liver to produce a greater secretion level of IGF-1. Also known as Insulin-like Growth Factor-1 or Somatomedin C, IGF-1 has been shown to exhibit highly reactive qualities. What this means is, it has been shown to be vital in the growth and repair of muscles and tissues. Because GHRP-2 has been shown to boost levels of IGF-1, it is thought that this ability along with its faculty for increasing protein synthesis can allow an animal test subject to experience a boosted level of muscle size and mass. What’s more, it has also led to the notion that it can promote a more efficient means of tissue repair, which can ultimately translate into a more efficient means of injury recovery.
Other Positive Effects
The proliferation of muscular and skeletal tissue is not the only elevated process that has been associated with GHRP-2. For example, scientific study that has been based on animal test subjects has led to the theory that its ability to increase protein synthesis can lead to a more efficient means of breaking down adipose tissue, also known as body fat. This then has led to the thought that the presence of the peptide can lead to an ability to lose weight more efficiently, despite the fact that GHRP 2’s ability to stimulate ghrelin could lead to an animal test subject increasing its food intake.
Other elevated process that scientific study based on animal test subjects has tied to GHRP-2’s functionality and operational mechanics include a lowering of cholesterol levels, and improved bone density an enhanced defense of the liver, an improved skin elasticity, and an enhanced measure of anti-inflammatory action.
Set Aside for Scientific Research
It should be emphasized that despite the extensive amount of research and study that has been conducted in order to pinpoint the functionality and mechanics of GHRP 2, it is only intended for the sole use of scientific study at this time. All of the research and findings that have been determined and discussed are completely built around the scientific study on animal test subjects. Because of this, any findings or observations that can be tied to GHRP-2’s overall functionality, mechanics, or theoretical benefits should exclusively be contained to a laboratory, a medical research facility, or another strictly controlled environment in this vein.
CJC-1295 without DAC
Mod GRF (1-29) 5mg (CJC-1295 no DAC)
Molecular formula: C152H252N44O42
Molar Mass: 3368.7
Synonyms: Mod GRF 1-29, CJC-1295 no DAC
Modified Growth Releasing Factor aminos 1-29, usually referred to as Modified GRF (1-29) or “ModGRF(1-29),” also known as CJC-1295 without DAC, is a synthetic analog of the endogenous peptide signaling hormone Growth Hormone Releasing Hormone (GHRH). Endogenously produced GHRH has 44 amino acids in its chain structure. A truncated synthetic form of GHRH called Sermorelin or GRF 1-29 has 29 amino acids; Modified GRF (1-29) is further changed in that it has four substituted aminos in its chain that serve the purposes of preventing degradation and oxidation in manufacture and transport as well as in vivo, while also increasing binding affinity to the GHRH receptors.
Modified GRF (1-29) is not CJC-1293 nor should it be referred to as such. Modified GRF (1-29) is identical to the portion of CJC-1295 DAC that is not bound to MPA, minus the lysine. The presence of lysine in a literal “CJC without DAC” in the absence of MPA would have the opposite effect of DAC: it would drastically reduce the active life of the peptide to that of Sermorelin. Modified GRF (1-29) is the same as CJC-1295 with out DAC.
Tetrasubstitued GRF (1-29)
Modified GRF (1-29) is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation.
CJC-1295 DAC vs. CJC-1295 No DAC
CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Growth Hormone.